Provectus Biopharmaceuticals announced in a press release that it has completed protocol for a phase1b/2 testing of its investigational drug PV-10 in combination with Keytruda in patients with stage IV melanoma.
MRV Research
FDA Grants Nivolumab/Ipilimumab Combination Priority Review for Advanced Melanoma
The FDA has granted a priority review designation to a supplemental biologics license application for nivolumab (Opdivo) plus ipilimumab (Yervoy) in previously untreated patients with advanced melanoma, according to a statement from the regimen’s developer, Bristol-Myers Squibb.
Preoperative PET/CT staging yields high false-positive rate in node-positive melanoma
Preoperative PET/CT staging for the detection of clinically occult metastatic melanoma among patients with sentinel lymph node-positive melanoma has a high false-positive rate and a minimal effect on management, according to retrospective study results.
Novel Discoveries May Hold Answers For Treatment-Resistant Melanoma
UCLA scientists have recently released study findings which may hold important implications in the field of metastatic melanoma research. The study entitled, “Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance“, was published in the journal Cell, and may possibly lead to new tests for the early detection of drug-resistant tumor cells, as well as, treatments that suppress possible resistance to targeted therapies.